Nephrology
Guidelines
‘Major update’ of BP guidance for kidney disease; treat to 120 mm Hg
“[Chapter one] of the guidelines is devoted to blood pressure measurement ... if [targeting] 120 [mm Hg systolic], the emphasis is on 120 measured...
From the Journals
Bone loss common in kidney stone patients, yet rarely detected
Almost one-quarter of patients diagnosed with kidney stones have osteoporosis or a fracture history on diagnosis, yet few undergo bone mineral...
Feature
Missed visits during pandemic cause ‘detrimental ripple effects’
ACP president says doctors are already seeing the consequences of postponing care.
News from the FDA/CDC
FDA approves voclosporin for lupus nephritis
The calcineurin inhibitor is the first oral treatment to be approved for lupus nephritis.
From the Journals
Severe renal arteriosclerosis may indicate cardiovascular risk in lupus nephritis
Statins were underused in a lupus nephritis cohort regardless of arteriosclerosis severity.
From the Journals
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
Five new cases of euglycemic diabetic ketoacidosis seen in T2D patients with acute COVID-19 illness.
From the Journals
New findings add to questions about existence of gouty nephropathy
“I think [the study is] a really good wake-up call to start looking, doing good detective work here, and looking especially in people who have...
News from the FDA/CDC
FDA expands belimumab indication to adults with lupus nephritis
The approval is based on the BLISS-LN trial, in which belimumab, when added to standard therapy, increased response rates and prevented worsening...
Guidelines
ADA 2021 standards address financial hardship in diabetes
In the year of COVID-19, new ADA standards include assessment of socioeconomic challenges, individualization of type 2 diabetes treatment, and...
Myth of the Month
Patient with CKD: Contrast or no contrast?
New guidelines help clarify why there is a diminished concern for contrast-induced kidney disease.
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...